CD155 expression on the surface of pancreatic duct adenocarcinoma cells is involved in the exhaustion of CD8+ T cells, while TIGIT neutralizing antibodies in combination with neutralizing antibodies to PD-1 will contribute to reinvigorating the tumor immune response and effectively inhibit the progression of pancreatic cancer [212]. The gene discussed is PDCD1; the disease is neoplasm.